-
What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.
Access to HealthcareClinical ResearchEthical BusinessMedicine Safety -
Basel, July 20, 2021 — Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools (HBCUs) to co-create programs that address the…Social CommitmentGlobal Health PartnershipsFuture of HealthcareEthical Business
-
Basel, December 14, 2020 — Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint1. Initial data show there was no statistically significant reduction in the proportion of patients on…Infectious DiseasesEthical Business
-
Basel, June 25, 2020 – Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA) investigations into historical conduct by the Company and its subsidiaries. As part of the settlements, Novartis and certain of its current and former…Social CommitmentReimagine MedicineEthical BusinessAd Hoc
-
Basel, July 2, 2020 – Novartis has finalized its previously disclosed agreement with the US Attorney’s Office for the Southern District of New York, the New York State Attorney General, and relator Oswald Bilotta resolving a civil suit challenging speaker programs and other promotional events conducted from 2002 through 2011 by Novartis…Reimagine MedicineEthical BusinessAd Hoc
-
Basel, July 16, 2020 — Today, Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment. Inflammation and respiratory problems linked to COVID-19 can cause…Reimagine MedicineEthical BusinessAccess to Healthcare
-
Basel, September 1, 2020 — Novartis will host a virtual investor event today to provide a comprehensive overview of the company’s progress in its Environmental, Social and Governance (ESG) strategy.Novartis AccessFuture of HealthcareEthical BusinessAd HocAccess to Healthcare
-
Patrice Matchaba shares how a lifetime of experience helped shape an effort to address healthcare disparities.
Access to HealthcareEthical BusinessSocial Commitment -
Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.
Access to HealthcareDiseasesEthical BusinessSocial Commitment -
COPD receives low attention as a women’s health issue. It’s time to change that.
Chronic IllnessDisease AwarenessEthical BusinessRespiratoryWomen in Science -
Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.
DigitalEthical BusinessMedicine Safety -
Jean Silveri shares key insights from her legal career.
Ethical BusinessNovartis Institutes for BioMedical ResearchWomen in ScienceWorking at NovartisCareers